Octreotide and octreotate derivatives radiolabeled with yttrium: pharmacokinetics in rats.
Distribution profiles and elimination pathways in rats of two new octreotate derivatives radiolabeled with yttrium, namely Y-DOTAGA-tate and Y-DOTA-t-GA-tate, were compared with those of Y-DOTA-octreotide and Y-DOTA-Tyr(3)-octreotide. All synthetic somatostatin analogues under study were rapidly cleared from the blood and most organs of rats. The main elimination pathway for all peptides under study was urine excretion. High and long-term uptakes of radioactivity in the kidneys and also in organs with high density of somatostatin receptors (the adrenals and pancreas) were found. Radioactivity concentrations in these somatostatin receptor-rich organs were substantially higher for octreotate derivatives in comparison with octreotide analogues; the highest values for Y-DOTAGA-tate were determined. The octreotate derivatives under study appear to be specific ligands for treatment of somatostatin receptor-positive tumors if some mechanism to decrease their kidney retention is provided.
Laznicek
M
M
Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic. Laznicek@faf.cuni.cz
Laznickova
A
A
Mäcke
H R
HR
Eisenwiener
K
K
Reubi
J C
JC
Wenger
S
S
D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D008297:Male; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D017481:Receptors, Somatostatin / Q000378:metabolism; D015021:Yttrium Radioisotopes
D001798:Blood Proteins; D017481:Receptors, Somatostatin; C473253:Y-DOTA-t-GA-tate; C473254:Y-DOTAGA-tate; D015021:Yttrium Radioisotopes; D015282:Octreotide